CFTR and cystic fibrosis: As there is insufficient evidence related to pregnancy‐related toxicity of CFTR modulators and it is off‐label in mothers carrying infants with CF, these clinical cases provide interesting insights; however, the risk is still present and for some payors, may not be covered in various situations and can be a large cost burden that will reduce equity in availability.